single blood draw

PROCEDURE4 trials

Sponsors

Heidelberg ImmunoTherapeutics GmbH, Wyeth is now a wholly owned subsidiary of Pfizer, University of Colorado, Denver, University of Oklahoma

Conditions

Cardiopulmonary BypassChronic Kidney DiseaseCongenital Heart DefectHemophilia AInflammationInflammatory ResponseLow Cardiac Output Syndromegenital herpes oral herpes B00

Phase 4

Study Evaluating Inhibitor Specificity in Hemophilia A

WithdrawnNCT00151385

Wyeth is now a wholly owned subsidiary of PfizerHemophilia A

Start: 2005-11-30End: 2007-10-31Updated: 2012-06-28

Unknown Phase

Endothelial Microparticles: A Novel Marker of Vascular Dysfunction

CompletedNCT02230202

University of Colorado, DenverChronic Kidney Disease

Start: 2014-09-30End: 2016-03-31Updated: 2018-02-28

Prognostic Markers of Inflammation in Infants Undergoing Cardiopulmonary Bypass

CompletedNCT03143348

University of OklahomaCardiopulmonary Bypass, Congenital Heart Defect, Inflammation +2

Start: 2017-06-04End: 2019-04-15Updated: 2019-04-30

Sample collection for an assay development to determine HSV-specific T-cell responses in blood samples from HSV-2 infected individuals and HSV-1 + HSV-2 infected individuals

Active, not recruitingDRKS00031143

Heidelberg ImmunoTherapeutics GmbHgenital herpes oral herpes B00

Start: 2023-02-14Target: 30Updated: 2025-04-07

Related Papers

Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease.

2018-07-1352 citations